Skip to main content
Sign In |
  Help (new window)
GRAZAX® is the first allergy tablet to adress the underlying cause for grass pollen allergy.

Grazax - Allergy Immunotherapy Tablet

Go SearchAdvanced Search
Grazax - Allergy Immunotherapy Tablet
About Grazax®
STAAR Newsletter
Calendar
Slide Sets
Questions from patients
Patient Support Website
Media Info
Publications
  
Grazax - Allergy Immunotherapy Tablet > Publications  

Publications

View All Site Content

Modify settings and columns
  
View: 
Sort by AttachmentsUse SHIFT+ENTER to open the menu (new window).
Sublingual ImmunotherapyUse SHIFT+ENTER to open the menu (new window).
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 yearsUse SHIFT+ENTER to open the menu (new window).
Cost-effectiveness of GRAZAX® for prevention of grass pollen induced rhinoconjunctivitis in Southern EuropeUse SHIFT+ENTER to open the menu (new window).
Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacyUse SHIFT+ENTER to open the menu (new window).
Influences of time horizon and treatment patterns on cost-effectiveness measures the case of allergen-specific immunotherapy with GRAZAX®Use SHIFT+ENTER to open the menu (new window).
Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symtoms, including nasal blockageUse SHIFT+ENTER to open the menu (new window).
Cost-effectiveness of grass allergen tablet (GRAZAX®) for the prevention of seassonal rhinoconjunctivitis - a Northen European perspectiveUse SHIFT+ENTER to open the menu (new window).
Specific immunotherapy with high dose SQ standardised grass allergen tablets was safe and well toleratedUse SHIFT+ENTER to open the menu (new window).
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitisUse SHIFT+ENTER to open the menu (new window).
Safety and immunological changes during sublingual immunotherapyUse SHIFT+ENTER to open the menu (new window).
Sublingual immunotherapy with once-daily grass allergen tablets A randomized controlled trial in seasonal allergic rhinoconjunctivitisUse SHIFT+ENTER to open the menu (new window).
Safety of a SQ standardised grass allergen tablet for sublingual immunotherapyUse SHIFT+ENTER to open the menu (new window).
Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitisUse SHIFT+ENTER to open the menu (new window).
Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: A double-blind, randomised studyUse SHIFT+ENTER to open the menu (new window).
Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Use SHIFT+ENTER to open the menu (new window).
Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of lifeUse SHIFT+ENTER to open the menu (new window).